Dendreon Announces Webcast Presentations at Upcoming Investor Conferences

SEATTLE, April 30 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following investor conferences in May.

The following presentations will be webcast:


Deutsche Bank 35th Annual Health Care Conference, Boston, MA

May 3, 2010

10:40 a.m. ET


Bank of America Merrill Lynch 2010 Health Care Conference, New York, NY

May 11, 2010

2:20 p.m. ET


Citi 2010 Global Health Care Conference, New York, NY

May 26, 2010

8:00 a.m. ET



The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.  

In addition, Dendreon will participate at:


Brean Murray, Carret & Co. 2010 Life Sciences Summit, New York, NY

May 17, 2010



Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

SOURCE Dendreon Corporation

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.